RxDoctor Payments Data

Sandra Quick

Family · Columbia, SCNPI 1649262288

Payments from drug & device makers

$1,060in general payments, 2019–2025

Across 73 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$514
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$99
  • Pfizer$98
  • Amgen$74
  • Novo Nordisk$60
  • Lilly USA, LLC$43
  • plus $172 from 9 others

What the payments were for

  • Food & beverage$1,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,060 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$135,292
Medicare patients
147
Services billed
2,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter119$109,781
LinzessLinaclotide141$103,968
EliquisApixaban144$102,330
OzempicSemaglutide86$99,483
MounjaroTirzepatide73$98,571
FarxigaDapagliflozin Propanediol97$77,356
JardianceEmpagliflozin64$60,768
TrulicityDulaglutide36$39,021
VraylarCariprazine Hcl18$29,132
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen137$25,644
Breo ElliptaFluticasone/Vilanterol36$24,785
XareltoRivaroxaban29$22,246
EntrestoSacubitril/Valsartan16$22,114
PentasaMesalamine14$19,639
RybelsusSemaglutide16$19,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar, Restasis$514$140,286170 claims
Lilly USA, LLCMounjaro, Trulicity$43$137,592109 claims
Novo NordiskOzempic, Rybelsus$60$118,985102 claims
PfizerEliquis$98$102,330144 claims
AstraZenecaFarxiga, Symbicort$22$83,766112 claims
Johnson & JohnsonXarelto$14$22,24629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →